Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20851771 | 0.92 | POLB (0.74) | POLBMEN1KMT2ARAB9AALDH1A1 | |
| SCHEMBL8987230 | 0.83 | KMT2A (0.63) | SMN1; SMN2POLBMEN1KMT2ARAB9A | |
| SCHEMBL6537209 | 0.83 | RAB9A (0.71) | SMN1; SMN2POLBMEN1KMT2ARAB9A | |
| SCHEMBL7696576 | 0.83 | KMT2A (0.68) | SMN1; SMN2POLBMEN1KMT2ARAB9A | |
| SCHEMBL6627891 | 0.81 | KMT2A (0.69) | SMN1; SMN2POLBMEN1KMT2ARAB9A | |
| SCHEMBL20941567 | 0.80 | TP53 (0.52) | GAAMEN1KMT2ARAB9ATP53 | |
| SCHEMBL10192214 | 0.80 | RAB9A (0.81) | SMN1; SMN2POLBMEN1KMT2ARAB9A | |
| SCHEMBL3223877 | 0.80 | RAB9A (0.81) | SMN1; SMN2POLBMEN1KMT2ARAB9A | |
| SCHEMBL17183464 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2GAAPOLBMEN1KMT2A | |
| SCHEMBL15033988 | 0.79 | CA12 (0.64) | SMN1; SMN2GAAMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731946-B2 | Broad spectrum antivirulence, anti-persistence compounds | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731946-B2 | Broad spectrum antivirulence, anti-persistence compounds | ME2, ME1, ME3 | SMN1; SMN2 1170/4885GAA 113/4885POLB 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.